We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Reality injection

7 June 2016 By Richard Beales

Joseph Papa says some of the troubled $8 bln drug firm’s businesses are doing fine. But weak earnings and yet another downgrade sent the stock plunging on Tuesday. At under 10 pct of its peak value last year, the new boss will be trying to persuade investors the only way is up.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)